Medtronic PlcMDT

Medtronic’s strongest current rail is the 2026-06-18 SEC EDGAR 10-K for the period ending 2026-04-24: $36.36B of revenue, $6.47B of operating income, $4.80B of net income attributable to parent and diluted EPS of $3.73. That gives today’s MDT file a clear earnings base before any story about devices, filings or digital sales is allowed to run ahead of the evidence.

Medtronic is a medical-device company, and the supplied product rail makes that operating reality less abstract. The 10-K names ENT products including the Straightshot M5 microdebrider handpiece, Integrated Power Console system, NIM Vital nerve monitoring systems, Propel and Sinuva Sinus Implants, and StealthStation ENT and StealthStation FlexENT navigation systems. The official digital ordering pages add the customer channel: Connect E-Store, Connect.Me, EDI and online tracking for orders, deliveries and invoices.

The filed financials show scale and cash generation, but also items that deserve close treatment. Assets were $93.03B, liabilities were $42.96B and stockholders’ equity attributable to parent was $49.46B at the 10-K period ending 2026-04-24. Cash and cash equivalents were $1.95B, short-term investments were $7.27B, operating cash flow was $7.33B, property, plant and equipment spend was $1.90B, inventory was $5.95B and diluted weighted average shares were 1.29B.

The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The current public sequence includes the 2026-05-18 8-K, the 2026-06-18 10-K and IRANNOTICE, a 2026-06-26 Form 3, a 2026-07-08 Form 144 and a 2026-07-09 Form 4. Those are disclosure events, not proof of a price trend.

What changed in the named news rail is concrete but narrow. The 2026-05-18 8-K says Brett Wall would depart as Executive Vice President and President, Neuroscience Portfolio, and names Dr. Ken Washington in the same announcement rail. The later SEC items keep the ownership and filing trail current. The product pages show how Medtronic sells and supports ordering digitally, but they do not supply adoption figures, new approvals or revenue by service.

The main unresolved question is not whether Medtronic is a real operating business. The 10-K answers that. The better question is how the company turns its device catalogue, digital ordering services and remote sales support into cleaner growth while managing inventory, cost of products sold and brand risk. The supplied evidence proves the machinery and the filings; it does not yet prove the next inflection.